NCT02470780View on ClinicalTrials.gov

Treating Bacterial Overgrowth in Parkinson's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Parkinson's DiseaseSmall Intestinal Bacterial Overgrowth
Interventions
DRUG

Rifaximin

Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.

DRUG

Placebo

Placebo matching Rifaximin treatment.

Trial Locations (1)

45219

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

University of Cincinnati

OTHER

NCT02470780 - Treating Bacterial Overgrowth in Parkinson's Disease | Biotech Hunter | Biotech Hunter